Sai Parenterals Limited (SAIPARENT)

SME Cap

Sai Parenterals Limited operates in Parenteral, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹466

-17.00 · -3.52%

Market cap ₹2,206 Cr

ThemesPharma Healthcare & Hospitals

Data qualityFresh enough for analysisQuote updated 21 Oct, 12:16 pm IST

Details

Quote21 Oct, 12:16 pm IST

Base fundamentals06 Oct 2026 · screener

Latest result16 Aug, 01:20 am IST

Score21 Oct, 04:30 am IST · v4.3-runtime-valuation

Tags02 May 2026

Coverage12/14 · 86%

Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)

Technical timing lens

Trend score and candlestick chart

61Bullish

SMA20 -3.2% / mo · MACD − · sector +4.3pp vs Nifty 500 (3M)

Stock trend: 36

Sector RS: 99

Sector 3M: -1.6% vs Nifty 500 -5.9%

Pharma FPI tailwindFlow only

FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence

Compare peers →

Technical chart

SAIPARENTD candles · FIT view-3.1%TODAY · PROVISIONAL

Latest price ₹466.00 on 2026-10-21

Daily history is available from 2026-04-02; the requested 1Y window is partially covered. Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.

Bar

-2.7%

RSI

MACD hist

-3.02

52W pos

22%

2026-10-21O ₹478.70H ₹488.15L ₹462.10C ₹466.00Vol 82,525 shIntraday candle

Up bar

Down bar

EMA 20

EMA 50

Volume + 20D avg

Result date

RSI(14)

MACD / signal

Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

SAIPARENTNifty PharmaNifty 500

SAIPARENT: -14.9%
Nifty 500: -5.6%
Nifty Pharma: -1.5%
Vs Nifty 500: -9.4 pp

Chart stats

19 Oct 2026

From 52W high: -31.6%
52W range position: 27%
ATR (14): 3.8%
Volume vs 20D: 0.61x
Avg traded value: ₹5.6 Cr
20D price channel: ₹480.9 - ₹540

Quarter ended 30 Jun 2026

Pending data

YoY comparison unavailable - result verdict pending data

Revenue: ₹178.7 Cr; YoY NDF
PAT: ₹7.9 Cr; YoY NDF
Operating margin: 13.2%; QoQ +1686 bps
PAT margin: 4.4%; QoQ +1136 bps

Filed 11 Aug 2026Full result & history →

Current-quarter concall

Transcript not linked yet

No source-linked earnings-call transcript is available for this company in the active results quarter.

Search Concall Intelligence

Technical snapshot

Positioning and participation

Insufficient history

Current trend context ranked against all active NSE stocks. It describes the chart; it is not a buy or sell signal.

RS percentile: 54; 20-day rank history unavailable
Stage 2 entry: Insufficient history; A stage read needs at least 170 adjusted daily sessions
Sector rotation: #1; leading · 198 stocks
Industry rotation: #11; leading · 85 stocks

Trend structure

Below 20-DMABelow 50-DMA— 200-DMA

RSI (14)

Weak momentum

MACD

Below signal

Histogram -3.02

Volume participation

0.8x average

So far vs 20-session average

20-session position

5% of range

₹462.1 low · ₹539.95 high

Relative performance

vs Nifty 500

1M: -1.9 pp; stock -5.4%
3M: -9.4 pp; stock -14.9%
6M: +2.3 pp; stock -1.3%
1Y: +13.8 pp; stock +19.1%

From 52W high

-31.6%

High ₹706

52W range position

27%

₹400 - ₹706

ATR (14)

3.8%

₹18.37

Avg traded value

₹5.6 Cr

20-session average

Current setup

No confirmed setup attached

Review the chart and detailed technical evidence before drawing a conclusion.

Open detailed technicals →

Research snapshot

What the evidence says now

Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.

Suggested next step

Check latest quarters

Result consistency is weak; verify whether the thesis is improving or deteriorating.

U-Score

Legacy · OVERVALUED

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Quarter ended 30 Jun 2026

Pending data

YoY comparison unavailable - result verdict pending data

Filed 11 Aug 2026

Open results browser →

Metric	This quarter	YoY	QoQ
Revenue	₹178.7 Cr	NDF	-9.7%
EBITDA	₹23.5 Cr	+396.2%	+760.7%
Operating margin	13.2%	-104 bps	+1686 bps
PAT	₹7.9 Cr	NDF	-39.8%
PAT margin	4.4%	+18 bps	+1136 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E: 106.00
P/B: —
EV/EBITDA: 47.77
Market Cap: 2206.00Cr

Profitability

ROE: 4.88%
ROCE: 5.28%
ROA: 0.98%
Dividend Y: —

Growth (CAGR)

Revenue 5Y: 57.78%
EPS 5Y: 51.83%
Revenue 3Y: 58.00%
EPS 3Y: 48.00%

Balance Sheet

Debt/Equity: 0.96
Interest Coverage: 2.05×
Altman Z: 2.36
Book Value: —

Cash Flow

FCF Yield: —
FCF Positive Y: 1/5
OCF: 93.00 Cr
EPS TTM: 3.23

Shareholding

Promoter Hold: 51.16%
Promoter Pledge: 0.00%
Momentum 52W: 32%

Financial History

Updated 20/10/2026

Revenue

₹ Cr

Latest: 381+133.7% vs prev

Net Profit

₹ Cr

Latest: 14.0+0.0% vs prev

Return on Equity

Latest: 2.9-81.1% vs prev

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Bearish setup

Trend is weak — long-term trend unclear. RSI 34.

SMA20 falling (~3.5% over last month) — short-term momentum negative.
RSI(14) at 34 — falling, no extreme reading.
MACD below signal, histogram expanding negatively — bearish momentum building.
34% off 52W high · 17% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

RS percentile

Insufficient history

1M return

-5.4%

3M return

-14.9%

6M return

-0.6%

1Y return

RS 1D

RS 20D

Sector rank

Industry rank

#11

Stage evidence

At least 170 daily sessions are required for the trend-stage read.

50-DMA

price below

200-DMA

unavailable

Sector

leading

Industry

leading

Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.

Relative-strength line vs Nifty 500 (base 100)

137 observations

19 Oct 2026Value 113.09+0.14%

RS vs Nifty 500113

Valuation & peers

U-Score 24 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies

OVERVALUED

Fundamental score breakdown

U band · OVERVALUED

Valuation0/30

Growth14/25

Quality0/20

Balance Sheet4/15

Cash Flow1/10

Piotroski

7/9 (+5)

Penalties

Raw sum

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

24/100 · legacy band OVERVALUED

Positive drivers

Piotroski is strong at 7/9.
Growth contributes 14/25 to the score.
Balance sheet contributes 4/15 to the score.

Main drags

Fair-value margin of safety is negative at -220.6%.
Valuation is weaker at 0/30; verify the latest quarterly trend.
Quality is weaker at 0/20; verify the latest quarterly trend.

Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA

Primary lens

PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.

Secondary checks

USFDA risk, launch pipeline, margin trend, domestic vs export mix.

Main risk check

Regulatory setbacks or one-off product cycles can distort valuation.

106.0

—

EV/EBITDA

47.8

ROE

4.9%

ROCE

5.3%

FCF Yield

—

Debt/Equity

1.0

MoS

-220.6%

Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 21 Oct 2026

v4.3-runtime-valuation

Final score

Previous: 24

Legacy U-Score band

OVERVALUED

Previous: OVERVALUED

Margin of safety

-220.6%

Previous: -232.3%

Score history

12 stored score snapshots. Latest stored move: +0 points.

21 Oct 2026

v4.3-runtime-valuation

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number

—

Growth-justified P/E

45.0

Growth-justified Value

₹145.35

-220.6% MoS

PEG

2.11

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗

Ticker

Name

Why peer

Score

ROE

MoS

Verdict

PANACEABIO

Small

Panacea Biotec Limited

Remus Pharmaceuticals Ltd.

Dishman Carbogen Amcis Limited

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Sai Parenterals Limited operates in Parenteral, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score

54Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 13th percentile of the scored universe and 9th percentile within Pharma. Main check: financial discipline is weak at 38/100.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026

management-trust-v1

14 docs text-extracted · 2 concalls text-extracted

Score band

Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank

13th percentile

overall median 67 · Pharma: 9th pctile, median 70 · SME: 14th pctile, median 64

Evidence depth

Financial-only

14 documents have extracted text, but claim history is not strong enough yet.

Claim delivery

Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence

What it measures

Reliability of management and financial delivery, using financial behaviour only.

Confidence

Treat this as an early read until more concalls and outcomes are matched.

Investor use

Needs extra due diligence; demand valuation comfort and recent improvement.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter

strong · holding, pledge, alignment

Cash flow

weak · profit to cash conversion

Balance sheet

acceptable · leverage and solvency

Discipline

weak · capital discipline

Results

watch · quarterly consistency

Trust positives

▸Promoter pledge is zero.

Trust risks

▸Only 1 years of positive FCF.
▸ROCE is low at 5.3%.
▸ROE is low at 4.9%.
▸ROCE trend is -7.4%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Compare Pharma stocks Browse Indian stocks starting with S Explore fundamental stock screeners Browse Indian investment themes

Related companies

Panacea Biotec Limited (PANACEABIO)Remus Pharmaceuticals Ltd. (REMUS)Beta Drugs Limited (BETA)Dishman Carbogen Amcis Limited (DCAL)Hikal Limited (HIKAL)

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

Source: Bse

Open source ↗

Verify on:NSE India ↗

All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.

Sai Parenterals Limited (SAIPARENT)

Trend score and candlestick chart

Technical chart

Relative performance and chart statistics

What the evidence says now

Financials

Quarter ended 30 Jun 2026

Fundamentals

Valuation

Profitability

Growth (CAGR)

Balance Sheet

Cash Flow

Shareholding

Revenue

Net Profit

Return on Equity

Technicals

Daily technical trend read

Relative Strength & Trend Stage

Valuation & peers

Fundamental score breakdown

Why this score?

Positive drivers

Main drags

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Stored run vs live recompute

Score history

Factor attribution

Modelled fair value

Comparable companies

Business, management & trust

Issuer presentation review pending

How to read this Trust Score

Forensic breakdown

Trust positives

Trust risks

Continue researching Sai Parenterals Limited

Important announcements & filings

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1 Oct - Intimation of Schedule of Analyst / Institutional Investor meetings under Regulation 30 (read with Para A of Part A of Schedule III) of SEBI (LODR) …

Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 30 Sep - Board approved CS resignation, appointed new CS and COO effective 30 September 2026.

Aug 2026 · Transcript

Aug 2026 · PPT

Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Intimation of schedule of Analyst/Institutional Investors Meeting scheduled to be held on 31st August, 2026

Announcement under Regulation 30 (LODR)-Press Release / Media Release 25 Aug - Noumed renewed a 3-year OTC supply deal with an Australian pharmacy chain, worth AUD 30 million.

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 25 Aug - Subsidiary renewed 3-year OTC supply deal with Australian pharmacy chain worth AUD 30 million (~Rs204 crore).

Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Aug - Submission of Newspaper Publication in Form PAS-1 for change or variation in the objects of utilisation of IPO Proceeds.

Announcement under Regulation 30 (LODR)-Newspaper Publication 20 Aug - Newspaper Publication of Notice of 25th Annual General Meeting of the Comapny for FY2025-26.

Jul 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 1 Jul - Noumed renewed exclusive OTC supply deal in Australia for AUD 202 million over 7.5 years, effective July 1, 2026.

Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 6 Jul - Board appointed secretarial, internal and cost auditors on 06 Jul 2026 and authorized CMD to explore growth opportunities.

Jul 2026 · Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 1 Jul - Subsidiary Noumed signed exclusive OTC supply agreement worth AUD 202 million for 7.5 years, effective 1 July 2026.